ACIU
AC Immune S.A.NASDAQHealthcare$2.76-1.08%ClosedMarket Cap: $280.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.85
P/S
61.36
EV/EBITDA
-2.89
DCF Value
$-0.06
FCF Yield
-32.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1927.3%
Net Margin
-1968.6%
ROE
-101.6%
ROA
-45.5%
ROIC
-113.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $338.0K | 100.0% | $-13.9M | $-14.3M | $-0.14 | — |
| FY 2025 | $3.6M | 100.0% | $-68.9M | $-67.3M | $-0.67 | — |
| Q3 2025 | $939.0K | 100.0% | $-16.2M | $-15.9M | $-0.16 | — |
| Q2 2025 | $1.3M | 100.0% | $-19.4M | $-21.2M | $-0.21 | — |
| Q1 2025 | $990.0K | 100.0% | $-19.4M | $-19.0M | $-0.19 | — |
| Q4 2024 | $1.1M | 100.0% | $-18.6M | $-15.8M | $-0.15 | — |
| FY 2024 | $27.3M | -129.1% | $-52.4M | $-50.9M | $-0.51 | — |
| Q3 2024 | $25.5M | 100.0% | $7.3M | $5.5M | $0.05 | — |
| Q2 2024 | $687.0K | 100.0% | $-21.0M | $-22.8M | $-0.23 | — |
| Q1 2024 | $0.00 | NaN% | $-20.1M | $-17.9M | $-0.18 | — |
| Q4 2023 | $14.8M | 100.0% | $-3.5M | $-4.7M | $-0.06 | — |
| FY 2023 | $14.8M | -268.9% | $-53.6M | $-54.2M | $-0.64 | — |